newsfilter
← Earnings
Earnings Releases·

Tempus AI, Inc. — Third Quarter 2026 Earnings Summary

  • **Financial Performance:** Q3 2026 revenue reached $411.5 million (up 23% YoY), while net loss narrowed significantly to $14.9 million from $80.0 million in Q3 2025; Adjusted EBITDA turned positive at $25.6 million versus $1.5 million the prior year.
  • **Guidance & Outlook:** The company raised full-year 2026 revenue guidance to $1.60–$1.605 billion (approx. 25% growth) and expects full-year Adjusted EBITDA of approximately $65 million.
  • **Strategic M&A & Capital:** Regulatory review for the Personalis acquisition was cleared with a shareholder vote scheduled for November 30, 2026, and the company repaid its entire $100 million revolving credit facility.
  • **Strategic Partnerships:** Tempus secured multi-year collaborations including a $137.5 million oncology data license with BMS, a $55 million Alzheimer's data license with Pathos, and a commercialization partnership with Merck and Moderna.
Company
TEMPUS AI INC
Sector
Healthcare
Industry
Health Information Services